secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2022-01-05T23:59:59+00:00
Accession:  0001157523-22-000027
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise reports positive Phase 1b results for EDG-5506 in Becker MD: biomarkers reduced 71-83%
--------------------------------------------------------------------------------

- EDG-5506 well tolerated with no serious adverse events; dizziness was mild and transient.
- CK reduced 71% and TNNI2 reduced 83% after two weeks, near healthy volunteer levels.
- Plasma and muscle exposures exceeded pharmacologically active levels from preclinical models.
- No effect on voluntary grip, shoulder, or hip strength; ARCH open-label study enrolling.
- Management webcast today at 9 a.m. ET to discuss findings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322000027/0001157523-22-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322000027/a52557938.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer